menu
    • menu
    [{"orgOrder":0,"company":"CMP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Potassium Phosphate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CMP Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"CMP Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by CMP Pharma

    Menu

    CMP Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CMP Pharma, Inc Announces that Atorvaliq, the First and Only FDA-approved Liquid Suspension of Atorvastatin is...

                            Details : Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.

                            Product Name : Atorvaliq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2023

                            Lead Product(s) : Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CMP Pharma, Inc Announces that Liqrev, the First and Only Ready-made FDA-approved Liquid Suspension of Sildena...

                            Details : Liqrev (sildenafil) is the PDE5 inhibitor and First and Only Ready-made FDA-approved Liquid Suspension is indicated for the treatment of pulmonary arterial hypertension.

                            Product Name : Liqrev

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 21, 2023

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Potassium Phosphate

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CMP Pharma's Potassium Phosphates Injection Receives FDA Shelf Life Extension for Specific Lots

                            Details : Potassium phosphate injection is a phosphate replacement that is used to treat or prevent hypophosphatemia (low phosphorus in the blood).

                            Product Name : Potassium Phosphate-Geneic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2023

                            Lead Product(s) : Potassium Phosphate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CMP Pharma, Inc Announces that Tadliq®, the First and Only FDA-approved Liquid Suspension of Tadalafil, is No...

                            Details : Tadliq is the first and only FDA-approved liquid oral suspension of tadalafil for adult patients with difficulty swallowing. Tadliq is indicated for the treatment of pulmonary arterial hypertension and ensures consistent dosing.

                            Product Name : Tadliq

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2022

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            CMP Pharma

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlodipine Besylate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CMP Pharma, Inc Announces that Norliqva®, the First and Only FDA-approved Liquid Solution of Amlodipine, is N...

                            Details : Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.

                            Product Name : Norliqva

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : Amlodipine Besylate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth